Login to Your Account

Pozen shares drop on CRL; manufacturing issues are cited

By Jennifer Boggs
Managing Editor

Monday, April 28, 2014
Pozen Inc. said it expects to fully address the third-party manufacturing issues raised in the FDA's complete response letter (CRL) for drug candidates PA8140/PA32540, but the latest delay for the gastrointestinal-friendly aspirin candidates opened the door for investor anxiety, including concerns that the company's strategy of combining two generic components might not make for a commercial success story.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription